Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study

Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, ra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Research in pharmaceutical sciences 2024-09, Vol.19 (5), p.489
Hauptverfasser:	Dongre, Sneha A, Kulkarni, Gauri A, Mishra, Akshay, Deshmane, Rutuja B, Sonar, Nameeta, Yashi, Kanica, Thapa, Damodar, Ghade, Nikhil, Kadoo, Sachin M, Krishnan, Archana R, Sonar, Sanjay M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Antibodies Care and treatment Complications and side effects Computers Dextrose Diabetes therapy Diabetics Evidence-based medicine Glucose Glycosylated hemoglobin Hypoglycemic agents Medical research Medicine, Experimental Pharmaceutical industry Services Type 2 diabetes Viral antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!